Intellectual Property India Publishes Patent Application for 'Anti-Mct1 Antibodies And Uses Thereof' Filed by Immunext, Inc.; and Amgen, Inc.

MUMBAI, India, April 20 -- Intellectual Property India has published a patent application (202618008162 A) filed by Immunext, Inc.; and Amgen, Inc., Lebanon, U.S.A., on Jan. 28, for 'anti-mct1 antibodies and uses thereof.'

Inventor(s) include Rothstein, Jay; Carriere, Catherine; Seregin, Sergey; Gobeil, Philipe; Lee, Grace Ki Jeong; Shigenaka, Kimberly, P.; Gordon, Marcia; Quon, Kim; Wang, Yong; Levy, Raphael, D.; Wang, Jordon, K.; Chambers, Ross; Tucker, David Francis; and Screnci, Brad A.

The application for the patent was published on April 17, under issue no. 16/2026.

According to the abstract released by the Intellectual Property India: "This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions in vitro and/or in vivo. The invention also relates to therapeutic and diagnostic uses of these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing optionally wherein these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing are used in therapeutic regimens that further include the administration of other therapeutic agents, e.g., mitochondrial inhibitors and/or biguanides or small molecule MCT1 inhibitors."

The patent application was internationally filed on Jan. 04, 2019, under International application No.PCT/US2019/012415.

Disclaimer: Curated by HT Syndication.